Cargando…
A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
BACKGROUND: Curene® is a bioavailable formulation of turmeric Curcucma longa extract comprising naturally derived curcuminoids formulated with proprietary Aquasome® technology. Curcuminoids were found to have anti-inflammatory properties by inhibiting Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222223/ https://www.ncbi.nlm.nih.gov/pubmed/30498758 http://dx.doi.org/10.1155/2018/5291945 |
_version_ | 1783369158296076288 |
---|---|
author | Panda, Sanjib kumar Nirvanashetty, Somashekara Parachur, Vivek A. Mohanty, Nilima Swain, Tathastu |
author_facet | Panda, Sanjib kumar Nirvanashetty, Somashekara Parachur, Vivek A. Mohanty, Nilima Swain, Tathastu |
author_sort | Panda, Sanjib kumar |
collection | PubMed |
description | BACKGROUND: Curene® is a bioavailable formulation of turmeric Curcucma longa extract comprising naturally derived curcuminoids formulated with proprietary Aquasome® technology. Curcuminoids were found to have anti-inflammatory properties by inhibiting Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzyme and hence have potential application in the treatment of Osteoarthritis (OA). To evaluate the safety and efficacy of Curene® a randomized, double blind, placebo controlled, parallel-group study was conducted in subjects with knee OA. Significant improvements in clinical endpoints were observed during the trial along with excellent safety profile. METHODS: Fifty (50) subjects aged between 40 and 75 years who were suffering from unilateral or bilateral OA of the knee for greater than 3 months according to American College of Rheumatology (ACR) criteria were enrolled. They were randomized into two treatment groups; one group received Curene® 500 mg once daily and the other group received placebo. Efficacy was evaluated using change from baseline in Visual Analogue Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Biochemical and hematological parameters including urine analysis were performed to evaluate the safety of Curene® in OA patients. RESULT: Forty-six (46) subjects completed the study. The reduction from baseline in total WOMAC score (also subscale scores) and VAS score resulted in statistically significant difference when compared to placebo. It was also found to be safe and well tolerated as there was no incidence of treatment related AEs. CONCLUSION: Curene® results in statistically significant and clinically meaningful reduction in pain, stiffness, and improvement in physical functioning in subjects suffering from knee OA. Curene® also demonstrates excellent safety profile during the study. TRIAL REGISTRATION: This trial is registered with Clinical Trial Registry, India, CTRI/2017/07/009044, registered on 14th July 2017, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=19264&EncHid=&userName=ocius%20life%20sciences. |
format | Online Article Text |
id | pubmed-6222223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-62222232018-11-29 A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA Panda, Sanjib kumar Nirvanashetty, Somashekara Parachur, Vivek A. Mohanty, Nilima Swain, Tathastu Biomed Res Int Clinical Study BACKGROUND: Curene® is a bioavailable formulation of turmeric Curcucma longa extract comprising naturally derived curcuminoids formulated with proprietary Aquasome® technology. Curcuminoids were found to have anti-inflammatory properties by inhibiting Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzyme and hence have potential application in the treatment of Osteoarthritis (OA). To evaluate the safety and efficacy of Curene® a randomized, double blind, placebo controlled, parallel-group study was conducted in subjects with knee OA. Significant improvements in clinical endpoints were observed during the trial along with excellent safety profile. METHODS: Fifty (50) subjects aged between 40 and 75 years who were suffering from unilateral or bilateral OA of the knee for greater than 3 months according to American College of Rheumatology (ACR) criteria were enrolled. They were randomized into two treatment groups; one group received Curene® 500 mg once daily and the other group received placebo. Efficacy was evaluated using change from baseline in Visual Analogue Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Biochemical and hematological parameters including urine analysis were performed to evaluate the safety of Curene® in OA patients. RESULT: Forty-six (46) subjects completed the study. The reduction from baseline in total WOMAC score (also subscale scores) and VAS score resulted in statistically significant difference when compared to placebo. It was also found to be safe and well tolerated as there was no incidence of treatment related AEs. CONCLUSION: Curene® results in statistically significant and clinically meaningful reduction in pain, stiffness, and improvement in physical functioning in subjects suffering from knee OA. Curene® also demonstrates excellent safety profile during the study. TRIAL REGISTRATION: This trial is registered with Clinical Trial Registry, India, CTRI/2017/07/009044, registered on 14th July 2017, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=19264&EncHid=&userName=ocius%20life%20sciences. Hindawi 2018-10-25 /pmc/articles/PMC6222223/ /pubmed/30498758 http://dx.doi.org/10.1155/2018/5291945 Text en Copyright © 2018 Sanjib kumar Panda et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Panda, Sanjib kumar Nirvanashetty, Somashekara Parachur, Vivek A. Mohanty, Nilima Swain, Tathastu A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA |
title | A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA |
title_full | A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA |
title_fullStr | A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA |
title_full_unstemmed | A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA |
title_short | A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA |
title_sort | randomized, double blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of curene® versus placebo in reducing symptoms of knee oa |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222223/ https://www.ncbi.nlm.nih.gov/pubmed/30498758 http://dx.doi.org/10.1155/2018/5291945 |
work_keys_str_mv | AT pandasanjibkumar arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT nirvanashettysomashekara arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT parachurviveka arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT mohantynilima arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT swaintathastu arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT pandasanjibkumar randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT nirvanashettysomashekara randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT parachurviveka randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT mohantynilima randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa AT swaintathastu randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa |